Stockreport

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]

Sagimet Biosciences Inc.  (SGMT) 
PDF Sagimet Biosciences Inc. Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom com [Read more]